Drug intelligence / Profile preview

18F-PFPN

Development stage: Phase 1
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-PFPN is a novel PET (Positron Emission Tomography) probe with high affinity and selectivity for melanin. It was developed as an improvement over previous melanin-targeted tracers, with higher tumor-to-normal liver ratio and radiochemical yield. The tracer is synthesized through a fluoro-for-tosyl exchange reaction and has been shown to be highly stable in vivo. 18F-PFPN has demonstrated superior diagnostic performance compared to traditional 18F-FDG PET in identifying both primary malignant melanoma (MM) and its distant metastases. Clinical studies have shown that 18F-PFPN is safe and well-tolerated in humans, with an effective absorbed dose comparable to that of 18F-FDG.

Other names: 18F-N-(2-diethylaminoethyl)-4-(2-[2-ethoxy]-ethoxy)pyridine

Beyond the preview

Go deeper on 18F-PFPN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-PFPN.

Explore the full profile